Ризедронат в лечении остеопороза: эффективность и переносимость


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

Ризедронат, относящийся к классу азотсодержащих бисфосфонатов, обладает высокой антипереломной активностью и способен снижать риски вертебральных, невертебральных переломов и переломов бедра при установленном постменопаузальном остеопорозе. По числу, спектру и тяжести побочных эффектов ризедронат не отличается от других бисфосфонатов.

Полный текст

Доступ закрыт

Об авторах

И. И Зубкова

Северо-Западный ГМУ им. И.И. Мечникова

Ю. А Сафонова

Северо-Западный ГМУ им. И.И. Мечникова

к.м.н.

Е. Г Зоткин

Северо-Западный ГМУ им. И.И. Мечникова

д.м.н.

Список литературы

  1. Black D.M., Cummings S.R., Karpf D.B., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41.
  2. Cummings S.R., Black D.M., Thompson D.E., et al. Fracture Intervention Trial Research Group. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial. JAMA 1998;280: 2077-82.
  3. Harris S.T., Watts N.B., Genant H.K., et al. for the VERT Study Group. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 1999;282:1344-52.
  4. Reginster J., Minne H.W., Sorensen O.H., et al., on behalf of the Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000;11:83-91.
  5. Chesnut III C.H., Skag A., Christiansen C., et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-49.
  6. Black D.M., Delmas P.D., Eastell R., et al., for the HORZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of osteoporosis. N Engl J Med 2007;356:1809-22.
  7. McClung M.R., Geusens P., Miller P.D., et al., for the Hip Intervention Program (HIP) Study Group. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001;344:333-40.
  8. Black D.M., Thompson D.E., Bauer D.C., et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. J Clin Endocrinol Metab 2000;85:4118-24.
  9. Pols H.A., Felsenberg D., Hanley D.A., et al., for the Fosamax International Trial Study Group. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Osteoporos Int 1999;9:461-68.
  10. Eastell R., Reid D., Watts N., et al. Risedronate induces rapid and sustained reductions in ver tebral fracture risk in postmenopausal women with established osteoporosis. Osteoporosis int 2000; 11(1 ):26.
  11. Masud T., McClung M., Geusens P. Reducing hip fracture risk with risedronate in elderly women with established osteoporosis. Clin interv Aging 2009;4:445-49.
  12. Harrington J.T., Ste-Marie L.G., Brandi M.L., et al. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue int 2004;74(2): 129-35.
  13. Wells G.A., Cranney A., Peterson J, et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008:1-CD004523.
  14. Sebba Al., Bonnick S.L., Kagan R., et al. Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis. Curr Med Res Opin 2004;20:2031-41.
  15. Cadarette S.M., Katz J.N., Brookhart A., et al. Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture. Ann intern Med 2008;148:637-46.
  16. Silverman S.L., Watts N.B., Delmas P.D., et al. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos int 2007;18:25-34.
  17. Curtis J.R., Westfall A.O., Cheng H., et al. Risedronate and alendronate intervention over three years (REALITY): minimal differences in fracture risk reduction. Osteoporos int 2009:20:973-78.
  18. Taggart H., Bolognese M.A., Lindsay R., et al. Upper Gi tract safety of risedronate: a pooled analysis of 9 clinical trials. Mayo Clin Proc 2002;77:262-70.
  19. Adachi J.D., Adami S., Miller P.D., et al. Tolerability of risedronate in postmenopausal women intolerant of alendronate. Aging (Milano) 2001;13:347-54.
  20. United States Food and Drug Administration. FDA drug safety communication: ongoing safety review of oral bisphosphonates and atypical subtrochanteric femur fractures. 3/10/2010. [Accessed June 25, 2011].
  21. Shane E., Burr D., Ebeling P.R., et al. Atypical subtrochanteric and diaphyseal femoral frac tures: report of a task force of the American Society for Bone and Mineral research. J Bone Miner Res 2010;25:2267-94.
  22. Karam R., Camm J., McClung M. Comment on yearly zoledronic acid in postmenopausal osteoporosis. N Engl J Med 2007;357: 712-13.
  23. Miller P.D., Roux C., Boonen S., et al. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the cockcroft and gault method: a pooled analysis of nine clinical trials. J Bone Miner Res 2005;20:2105-15.
  24. Masoodi N. Oral bisphosphonates and the risk of osteonecrosis of the jaw. BJMP 2009;2:11-5.
  25. American Association of Oral and Maxillofacial Surgeons. Position paper on bisphosphonaterelated osteonecrosis of the jaws. September 25, 2006 [Accessed June 25, 2011].
  26. Cardwell C.R., Abnet C.C., Cantwell M.M., Murray L.J. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 2010;304:657-63.
  27. Pazianas M., Cooper C., Ebetino F.H., Russell R.G. Long-term treatment with bisphosphonates and their safety in postmenopausal women. Ther Clin Risk Manag 2010;6:325-43.
  28. Tan Y.L., Sims J., Chee S.P. Bilateral uveitis secondary to bisphosphonate therapy. Ophthalmologica 2009;223:215-16.
  29. French D.D., Margo C.E. Post marketing surveillance rates of uveitis and scelritis with bisphosphonates among a national veteran cohort. Retina 2008;28:889-93.
  30. Mussette P., Brandi M.L., Cacoub P., et al. Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug induced hypersensitivity. Osteoporos Int 2010;21:23-32.
  31. Halabe A., Lifschitz B.M., Azuri J. Liver damage due to alendronate. N Engl J Med 2000;343:365-66.
  32. Bone H.G., Hosking D., Devogelaer J.P., et al., for the Alendronate Phase III Osteoporosis Treatment Study Group. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189-99.
  33. Mellstrom D.D., Sorensen O.H., Goemaere S., et al. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004;75:462-68.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО «Бионика Медиа», 2012

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах